| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8442054 | European Journal of Cancer | 2015 | 9 Pages |
Abstract
Some patients with melanoma achieved long-term survival with vemurafenib monotherapy. Continuation of vemurafenib after PD might be beneficial in some patients because remaining disease might continue to respond to BRAF inhibition.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Igor Puzanov, Ravi K. Amaravadi, Grant A. McArthur, Keith T. Flaherty, Paul B. Chapman, Jeffrey A. Sosman, Antoni Ribas, Mark Shackleton, Patrick Hwu, Bartosz Chmielowski, Keith B. Nolop, Paul S. Lin, Kevin B. Kim,